Human RCTHumanRandomizedBlindedControlled
Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults
Sam L. Teichman, Ann Neale, Betty Lawrence, Catherine Gagnon, Jean-Paul Castaigne, Lawrence A. Frohman
Study design
Methods snapshot
- Population
- Healthy adults aged 21–61 years
- Sample size
- Not indexed
- Intervention
- CJC-1295
- Route
- Subcutaneous
- Dose reported
- Ascending single doses and weekly or biweekly multiple doses; the abstract identifies 30 or 60 µg/kg as particularly well tolerated
- Frequency
- Single administration; weekly or biweekly in the multiple-dose trial
- Duration
- 28 and 49 days
- Control / placebo
- Controlled study
Outcomes
Primary
- Peak concentration and area under the curve of GH and IGF-1
- CJC-1295 pharmacokinetics
Results
The report describes dose-dependent, sustained increases in mean GH and IGF-1 concentrations and an estimated half-life of 5.8–8.1 days.
Interpretation
Supports a human pharmacokinetic and pharmacodynamic effect on the GH/IGF-1 axis; it does not establish broader performance, body-composition or longevity claims.
Adverse events
- No serious adverse reactions were reported in the abstract.
Limitations
- Small early-phase pharmacology studies
- Clinical outcomes beyond endocrine biomarkers were not established
Connected records
Original source
Sempre consulte o artigo original para métodos completos, análises e contexto editorial.
Open PubMed record ↗